<DOC>
	<DOCNO>NCT02732405</DOCNO>
	<brief_summary>To assess efficacy ( SVR rate ) MK5172 / MK8742 12 week without RBV G1b patient compensate cirrhosis ( Child-Pugh A5 A6 ) previously fail first gen. PI non responder PR .</brief_summary>
	<brief_title>Study Investigate Tolerability Efficacy MK5172 / MK8742 Without Ribavirin 12 Weeks Patients With Chronic HCV G1b Infection With Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Informed consent form sign , 2 . Age &gt; 18 year , 3 . Chronic infection Hepatitis C virus genotype 1b , 4 . HCV RNA &gt; 100 IU/mL , 5 . HCV patient previously treat PR response previously treat first generation PIs ( boceprevir , telaprevir , simeprevir ) fail therapy , 6 . Subjects compensate cirrhosis ChildPugh score range A5 A6 . Cirrhosis define liver biopsy ( METAVIR F4 ) noninvasive method ( transient elastography ( FibroScan ) &gt; 12.5 KPa ; FibroTest FibroSure &gt; 0.75 APRI &gt; 2 ) , 7 . Hepatic Venous Pressure Gradient ( HVPG ) &gt; 6 mmHg ( select site ) , 8 . Albumin level ≥ 3.0 g/dl , 9 . Platelet count ≥ 75 x 103/μL . 1 . ChildPugh score great CPA6 , 2 . Patients HCV genotype 1a , 2 , 3 , 4 , 5 , 6 , 3 . Have serious active medical illness , opinion investigator , would interfere subject treatment , assessment , compliance , 4 . HIV chronic hepatitis B virus ( HBV ) infection ( HBsAg positive ) , 5 . Decompensated cirrhosis/previous decompensation , 6 . Pregnancy , 7 . Breastfeeding , 8 . Known hypersensitivity Grazoprevir , Elbasvir component , 9 . Albumin level &lt; 3.0 g/dl , 10 . Platelet count &lt; 75 x 103/μl , 11 . Concomitant participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>